8-K: Day One Biopharma Sells Priority Review Voucher for $108 Million

Day One Biopharmaceuticals has sold its Rare Pediatric Disease Priority Review Voucher for $108 million, strengthening its financial position.

Summary

• Day One Biopharmaceuticals sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $108 million in cash.
• The sale closed simultaneously with the signing of the asset purchase agreement on May 29, 2024.
• As part of the transaction, $8.1 million will be paid to Viracta Therapeutics, Inc. due to a prior licensing agreement.
• The PRV was awarded by the FDA to encourage the development of treatments for rare pediatric diseases.
• Day One received the PRV following the approval of their drug OJEMDA (tovorafenib) on April 23, 2024.
• OJEMDA is approved for treating patients 6 months and older with relapsed or refractory pediatric low-grade glioma with specific genetic mutations.
• The company plans to use the funds to support the launch of OJEMDA and invest in further clinical development.

Sentiment

Score: 8

Explanation: The document is positive due to the significant non-dilutive funding secured through the PRV sale, which strengthens the company's financial position and supports its growth plans. The company has a clear path forward with its approved drug and pipeline.

Positives

• The $108 million from the PRV sale provides significant non-dilutive capital.
• The sale strengthens the company's balance sheet.
• The funds will support the ongoing launch of OJEMDA.
• The company can invest in clinical development opportunities for both children and adults with cancer.
• The company has a cash runway into 2026.

Negatives

• The company is obligated to pay $8.1 million to Viracta Therapeutics from the proceeds of the PRV sale.
• The company is still reliant on the success of OJEMDA and its pipeline.

Risks

• The company's future success depends on the commercial success of OJEMDA.
• Clinical trials for other pipeline products may not be successful.
• The company faces risks related to global business and macroeconomic conditions.
• There are risks associated with inflation, rising interest rates, and geopolitical conflicts.
• The company's ability to protect intellectual property is a risk.

Future Outlook

The company plans to use the proceeds from the PRV sale to support the launch of OJEMDA and invest in clinical development opportunities, with a cash runway into 2026.

Management Comments

• Charles York II, chief operating and financial officer of Day One, stated that the sale of the PRV delivers true non-dilutive capital and further strengthens the balance sheet.
• Management is focused on executing the launch of OJEMDA and investing in clinical development.

Industry Context

The sale of the PRV is a strategic move to secure non-dilutive funding, which is common in the biotech industry, especially for companies focused on rare diseases. This allows Day One to continue its development programs without relying solely on equity financing.

Comparison to Industry Standards

• The sale of a PRV for $108 million is within the typical range for such transactions, although the value can vary based on market conditions and the specific drug associated with the voucher.
• Companies like BioMarin Pharmaceutical and Ultragenyx Pharmaceutical have also utilized PRVs to generate non-dilutive capital.
• Day One's focus on pediatric cancer aligns with a growing trend in the industry to address unmet needs in rare diseases.
• The company's pipeline, including tovorafenib and pimasertib, is comparable to other companies developing targeted therapies for cancer.

Related Party Transactions

• The company will pay $8.1 million to Viracta Therapeutics as part of the PRV sale agreement, due to a prior licensing agreement.

Stakeholder Impact

• Shareholders will benefit from the strengthened financial position and the potential for future growth.
• Patients will benefit from the continued development and availability of cancer therapies.
• Employees will benefit from the company's continued growth and stability.
• The company's partners will benefit from the company's continued success.

Next Steps

• The company will continue the launch of OJEMDA.
• The company will invest in clinical development opportunities.
• The company will advance the FIREFLY-2 and FIRELIGHT-1 clinical trials.
• The company will explore selective partnerships.

Key Dates

Keywords

Priority Review Voucher, PRV, OJEMDA, tovorafenib, pediatric low-grade glioma, pLGG, BRAF mutation, cancer therapy, biopharmaceutical, FDA approval